How Can We Rescue Promising Therapies from Clinical Development's "Valley of Death"?

The key seems to be distinguishing avoidable errors from inevitable risks

The "Valley of Death" (VoD) refers to the critical transitional stage where a drug candidate, having shown promise in in vitro and in vivo preclinical models, enters human clinical trials. It's here, typically during Phase I (safety), Phase II (efficacy and dose-ranging), and early Phase III (larger-scale efficacy and safety), that the highest rates of …